ClinicalTrials.Veeva

Menu

The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS

I

Immunexpress

Status

Terminated

Conditions

SIRS
Sepsis

Treatments

Other: SeptiCyte Lab molecular diagnostic test (non-interventional)

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT02704871
IXP 04-01b

Details and patient eligibility

About

A non-interventional, prospective observational study to assess the performance of SeptiCyte® Lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from infection-negative SIRS

Full description

This study is evaluating a molecular diagnostic device developed to distinguish between sepsis and infection-negative SIRS among critically ill patients.

This study is a prospective, non-randomized, non-interventional, observational trial of patients with suspected sepsis in the medical and/or surgical wards. The study is being conducted on two preselected patient care units.

All patients identified by a local screening tool undergo physician review. If the suspicion of sepsis is found to be plausible, routine and conventional diagnostic procedures, including: routine bloods, blood culture and specialized tests are conducted.

Blood collection for SeptiCyte® Lab and SeptID® is drawn within 6 hours of a positive screen - both use peripheral blood as the clinical sample. The diagnostic performance of the two experimental assays will be compared to Retrospective Physician Diagnosis (RPD), and conventional microbiological culture. The results of SeptiCyte® Lab and SeptID® are not used in any clinical decision-making.

This data will be used to analyze the performance of SeptiCyte® Lab according to the endpoint measures.

Enrollment

66 patients

Sex

All

Ages

18 to 89 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. 18-89 years old on the day of enrollment.

  2. Currently admitted to study designated medical or surgical ward

  3. Have a clinical suspicion of sepsis as determined by two physicians after identification by hospital screening tool.

  4. Screened positive for sepsis, severe sepsis or septic shock using the RISE2 screening tool.

  5. Completed SBAR handover (Situation, Background, Assessment, Recommendation)

  6. SIRS present as defined by the presence of two or more of the following:

    • Temperature > 38°C or < 36°C
    • Heart Rate > 90 beat/min
    • Tachypnea > 20/min or PaCO2 < 32 mmHg
    • WBC count > 12 000/mm3 or < 4 000/mm3 or > 10% immature neutrophils (bands)

Exclusion criteria

  1. Consent not provided
  2. Patients less than 18 years of age, or 90 years of age or older.
  3. Patients for which a blood sample could not be taken within 24 hours of a physician first determining a clinical suspicion of sepsis.
  4. Patients that are not located in the designated medical or surgical ward associated with the study.
  5. Patients listed for "Comfort Measures Only".
  6. Less than 2 SIRS criteria
  7. Commencement of narrow spectrum directed antibiotics prior to screening.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems